Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Investors are worried how the company will handle the 2028 expiration of the U.S. patents protecting Keytruda, Merck’s ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...